Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study ; volume:99 ; number:7 ; day:1 ; month:6 ; year:2020 ; pages:1615-1625 ; date:7.2020
Annals of hematology ; 99, Heft 7 (1.6.2020), 1615-1625, 7.2020
- Urheber
-
Zerbit, Jeremie
Chevret, Sylvie
Bernard, Sophie
Kroemer, Marie
Ablard, Charlotte
Harel, Stephanie
Brice, Pauline
Madelaine, Isabelle
Thieblemont, Catherine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-020-04045-y
- URN
-
urn:nbn:de:101:1-2020082120233823141072
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zerbit, Jeremie
- Chevret, Sylvie
- Bernard, Sophie
- Kroemer, Marie
- Ablard, Charlotte
- Harel, Stephanie
- Brice, Pauline
- Madelaine, Isabelle
- Thieblemont, Catherine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ibrutinib for B cell malignancies
Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma
Drug Review: Ibrutinib
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
Extrahepatic metabolism of ibrutinib
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie
The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
Ibrutinib for B cell malignancies
Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma
Drug Review: Ibrutinib
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
Extrahepatic metabolism of ibrutinib
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie
The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
Ibrutinib for B cell malignancies
Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma
Drug Review: Ibrutinib
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
Extrahepatic metabolism of ibrutinib
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie
The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib